JSPR - Jasper Therapeutics, Inc.
| Previous close | 1.5900 |
| Open | 1.5700 |
| Bid | 1.5900 x 1300 |
| Ask | 1.6000 x 800 |
| Day's range | 1.5700 - 1.6300 |
| 52-week range | 0.3860 - 3.8000 |
| Volume | |
| Avg. volume | 659,476 |
| Market cap | 176.522M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRAnnounced Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta ThalassemiaStrengthened the Board of Directors and Management Team wit
- GlobeNewswire
Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board
Pioneering Researcher in the Investigation of the Biology and Pathology of Mast Cells to Enhance Scientific Advisory Board’s ExpertiseREDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell tra
- GlobeNewswire
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human Resources
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Matthew Ford as the Company’s Vice President, Human Resources. “Mat
- GlobeNewswire
Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations
REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company’s Senior Vice President, Development Op
- GlobeNewswire
Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that it will participate at the Cantor Fitzgerald The Future of Oncology Virtual Symposium, to
- GlobeNewswire
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Daniel Adelman, M.D., as the company’s Acting Chief Medical Officer
- GlobeNewswire
Jasper Therapeutics to Present at Upcoming Conferences
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that the Company will be participating in the following conferences in March. William Blair’s Innovator Serie
- GlobeNewswire
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update
Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous UrticariaPresentation of Key Briquilimab Clinical Data, Including Initial Results in Stem Cell Transplant for Sickle Cell Disease and One Year Follow-Up for Acute Myeloid Leukemia Transplant PatientsRaised $101.4 Million Net Proceeds in January 2023 REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focu
- GlobeNewswire
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors
REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of healthcare industry veteran Vishal Kapoor, Partner of Avego Management, to Jasper’
- GlobeNewswire
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved through six months for the first patient and through three months for the second patientBoth patients are doing well post-transplant with briquilimab-based conditioning REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody ther
- GlobeNewswire
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR
Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning with briquilimab in combination with fludarabine and low dose irradiationOral Presentation, Abstract #86: All 12 patients at Stanford receiving briquilimab-based conditioning and donor cell infusion in an outpatient setting were discharged from the hospital the same day, requiring zero days inpatientPoster
- GlobeNewswire
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients
Data Presented in Plenary Session at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRFirst two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-upThird sickle cell disease participant has now achieved 100% donor myeloid chimerism through 30 days follow-upAll three participants have increased their hemoglobin at last follow-up relative to baseline REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeut
- GlobeNewswire
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced that, on February 2, 2023, it granted an option to purchase 1,093,831 shares of Jasper’s voting com
- GlobeNewswire
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023
REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it will host an investor conference call and webcast to provide a corporate update on Tuesday,
- GlobeNewswire
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the closing of its previously announced underwritten public offering of 69,000,000 shares of its co
- GlobeNewswire
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each shar
- GlobeNewswire
Jasper Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common sto
- GlobeNewswire
Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Three abstracts highlight the safety and efficacy of briquilimab combined with low-toxicity radiation conditioning to achieve full donor engraftment and leukemia disease eradication Data demonstrates that briquilimab is safe and well-tolerated as a conditioning agent in older patients, median age 70, with AML/MDS undergoing allogeneic hematopoietic cell transplantationDurable remissions achieved in 8 of the first 12 AML patients treated at one-year follow upLower than expected rates of severe ac
- GlobeNewswire
Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases
REDWOOD CITY, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem cell transplant conditioning agents targeting c-Kit, today announced, as part of an overall portfolio prioritization, that the Company will focus on the development of its lead product candidate, briquilimab (formerly known as JSP191), in chronic diseases and stem cell transplant for rare diseases. This
- GlobeNewswire
Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic cell transplant (HCT) therapies, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT.
- GlobeNewswire
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within 12-16 daysFirst two participants with peripheral blood chimerism at 60 days after allogeneic stem cell transplant achieved 100% donor myeloid chimerismFirst participant treated has a total hemoglobin level of 13.3 g/dL at five months follow up, increased from 8-9 g/dL at baseline REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JS
- GlobeNewswire
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia PatientsFast Track Designation Granted to JSP191 for Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell TransplantFirst Patient Enrolled in New Study of Addition of JSP191 to Non-myleoablative Hematopoietic Stem Cell Transplantation for Sickle Cell Disease and Beta-Tha
- GlobeNewswire
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to infuse with no treatment-adverse events or toxicities observedREDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at th
- GlobeNewswire
Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi anemia and Sickle Cell DiseaseOn track to initiate a new study of JSP191 as a therapeutic in second-line therapy for patients with lower-risk MDS later this year REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company fo
- GlobeNewswire
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia On schedule to initiate a registrational study in AML in the first quarter of 2023 On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lower-risk, transplant ineligible MDS patients later this year REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies f
